Indiens größter Arzneimittelhersteller Sun Pharma schließt einen Deal mit der US-Regierung, um Amerikanern billigere Medikamente zu liefern.

India’s largest drugmaker, Sun Pharmaceutical Industries, has reached a landmark agreement with the U.S. government to supply affordable medicines to American patients through a “Most Favoured Nation” (MFN) pricing model. The deal was announced during a meeting at the White House on August 31, 2026, where U.S. President Donald Trump met with Richard Ascroft, the company’s North America CEO. During the session focused on healthcare affordability, the two parties formalized the arrangement, which aims to lower prescription costs for millions of Americans. Under the terms of the agreement, Sun Pharma will offer its medications at the lowest available prices to state Medicaid programs in the U.S. This pricing structure ensures that buyers, primarily public health insurance systems, can access cost-effective treatments. According to a regulatory filing made by the company on Tuesday, the MFN pricing policy will also apply to all future innovative medicines launched by Sun Pharma in the U.S. market. This means that once new drugs hit the shelves, they will be priced competitively, potentially benefiting both public and private sectors. The deal comes amid ongoing efforts by the U.S. government to curb rising prescription drug costs. The country has long faced criticism for having some of the highest medication prices globally, with costs often exceeding those in other developed nations by nearly threefold. To address this issue, the administration has pursued multiple agreements with pharmaceutical firms. This latest collaboration with Sun Pharma adds to a growing list of over 20 such deals, involving companies from around the world. Sun Pharma’s participation in these initiatives reflects its strategic focus on the U.S. market. The company has been steadily expanding its footprint in the West, driven by investments in research, manufacturing, and commercialization. Earlier this year, it finalized a $11.75 billion acquisition of Organon & Co., further strengthening its position in the American healthcare landscape. The company currently holds the second-largest share of prescriptions in the U.S. dermatology sector and is actively entering new therapeutic areas, including immunology, cutaneous oncology, and ophthalmology. The agreement also highlights the company’s commitment to innovation and its role in shaping the U.S. pharmaceutical industry. Sun Pharma claims that its global portfolio of innovative medicines now constitutes approximately 22 percent of its total sales. This underscores the company’s dual strategy of leveraging generic drug production while investing heavily in cutting-edge therapies. As part of the deal, the U.S. government has postponed the application of Section 232 tariffs on Sun Pharma’s innovative products for more than two years. These tariffs, which are typically imposed on imports deemed harmful to national security, have been delayed as recognition of the company’s substantial investment in the U.S. However, specific details regarding the financial implications or exact terms of the tariff relief remain undisclosed. Richard Ascroft emphasized the importance of the U.S. market for Sun Pharma’s growth and expansion plans. He noted that the country plays a pivotal role in the company’s global operations, particularly in clinical development, sales, marketing, and manufacturing of both active pharmaceutical ingredients (APIs) and finished products. His remarks underscored the mutual benefits of the partnership, which aligns with broader economic and health policy goals. The impact of this deal extends beyond immediate cost savings. It signals a shift toward greater transparency and competition in the U.S. drug market, potentially influencing how other pharmaceutical companies approach pricing strategies. With continued pressure from regulators and consumers for more affordable options, such collaborations may become increasingly common in the coming years.